Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) modelsM.J. O’Connor, J.F. Liu, Zhongwu Lai et al.|European Journal of Cancer|2016Cited by 3
8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinicDarren Hodgson, M.J. O’Connor, H.D. Mason et al.|European Journal of Cancer|2014Cited by 0